The MTNAP1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Jurkat cells with targeted disruption of the MTNAP1 gene. This heterogeneous knockout model eliminates clonal selection artifacts, providing a robust system to investigate mitochondrial nucleoid functions.
The parental Jurkat cell line is an immortalized human CD4+ T-lymphoblastoid line derived from acute T-cell leukemia. It is a well-established model for T-cell receptor signaling, cytokine production, and apoptosis, making it ideal for examining how mitochondrial processes influence T-cell biology and leukemogenesis.
MTNAP1 is a mitochondrial nucleoid-associated protein essential for mtDNA packaging, replication, and transcription. Its activity is regulated by upstream factors like PGC-1??, NRF1, TFAM, and AMPK in response to cellular stress (hypoxia, ROS). MTNAP1 interacts with TFAM, POLG, TFB2M, LONP1, and the ClpXP protease. Gene disruption impairs mtDNA topology, reducing expression of key mitochondrial transcripts (MT-CO1, MT-ND1, MT-ATP6) and compromising respiratory chain function. This triggers intrinsic apoptosis via BCL-2 family proteins, cytochrome c, and caspase-9.
In the Jurkat T-cell leukemia context, MTNAP1 knockout permits dissection of mitochondrial nucleoid protein roles in lymphocyte metabolism and cell death. The loss of MTNAP1 likely shifts metabolic reliance, elevates ROS, and sensitizes cells to apoptosis, linking mtDNA maintenance to leukemic cell survival and T-cell activation pathways.
This polyclonal knockout pool is suitable for Western blotting, RT-qPCR of mtDNA transcripts, mtDNA copy number analysis, and Seahorse metabolic flux assays. Apoptosis and ROS can be measured by annexin V flow cytometry and ROS probes; T-cell activation can be monitored via CD69. Applications include mitochondrial dysfunction in T-cell leukemia, drug screening, and metabolic reprogramming studies. For more information, contact Ascent Research.
